Antitumor Activity of AZD0754, a dnTGFβRII-Armored, STEAP2-Targeted CAR-T Cell Therapy, in Prostate Cancer

Studies revealed that six-transmembrane epithelial antigen of prostate-2 (STEAP2) was a prevalent prostate cancer antigen that displayed high, homogeneous cell surface expression across all stages of disease with limited distal normal tissue expression.